Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
Baruah will lead strategy, growth, and transformation across the HLS vertical, focusing on expanding digital health capabilities and accelerating AI adoption
7-OH is a concentrated byproduct of the kratom plant and has shown potential for abuse by binding to opioid receptors
cSCC is one of the most common cancers in the U.S. and globally
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
The submission is supported by results from the Phase 3b APEX study
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
Subscribe To Our Newsletter & Stay Updated